Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infection

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

A limited number of large-scale population-based studies regarding the causality between COVID-19 and respiratory aspergillosis exist. Herein, using nationwide data, we investigated whether SARS-CoV-2 infection increases incidence of respiratory aspergillosis and impact of COVID-19-associated aspergillosis on severity of COVID-19. Further, to assess the biological impact of SARS-CoV-2 infection on airway structural and immune cells, we analyzed publicly available COVID-19 transcriptomic datasets.

Study Design and Methods

Utilizing a nationwide cohort of 8.5 million clinical registries, we included over 550,000 patients diagnosed with COVID-19 between October 8, 2020, and December 31, 2021, along with control-matched group. The primary outcomes were aspergillosis incidence, including both invasive and non-invasive forms, and its impact on the severity of COVID-19.

Results

COVID-19 was closely associated with increased incidence of subsequent respiratory aspergillosis. Comorbidities, including diabetes and COPD, increased the incidence of fungal infections in COVID-19 patients. Regarding severity of COVID-19, both invasive and non-invasive aspergillosis exacerbated the severity of the disease. Particularly, systemic corticosteroids had an overwhelming impact on the increased severity and mortality in both forms of aspergillosis. Notably, antifungal-related genes and pathways, including CCR6, CXCL9, and CX3CR1, were consistently downregulated following SARS-CoV-2 infection and/or corticosteroid treatment.

Interpretation

Our findings indicate that COVID-19 increases the incidence of respiratory aspergillosis. Moreover, respiratory aspergillosis, irrespective of its clinical invasiveness, significantly exacerbates the severity of COVID-19. Well-designed studies on the therapeutic potential of antifungal agents to improve the outcomes of COVID-19 are warranted.

Article activity feed